🇺🇸 FDA
Pipeline program

Aflibercept 8 mg

VGFTe-HD-OD-2444

Phase 3 small_molecule active

Quick answer

Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration is a Phase 3 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Neovascular Age-Related Macular Degeneration
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials